Mumbai, November 13, 2025: Lupin Limited (Lupin), a leading global pharmaceutical organization, today announced that it has secured an S&P Global ESG Score of 91 for 2025, significantly higher than the pharmaceutical industry average of 28. This accomplishment places Lupin among a select group of global companies that have exceeded the 90-point threshold.*
The impressive rise from 17 in 2021 represents one of the fastest ESG score improvements within the pharmaceutical industry, solidifying Lupin’s reputation as a champion of sustainable growth.
Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin, said, “Achieving a score above 90 in the S&P Global ESG ratings is a rare and notable global recognition, reflecting our deep-rooted commitment to sustainability. With a 15-point year-on-year increase, Lupin not only leads its industry peers but also sets higher standards for responsible and sustainable expansion. Our purpose-driven framework ensures that we consistently deliver healthcare solutions that create enduring value for patients, communities, and stakeholders worldwide.”
Lupin has made considerable strides across the Environmental, Social, and Governance pillars. It has enhanced renewable energy usage, reduced carbon emissions, and attained water-positive operations. Socially, the company has strengthened diversity and inclusion efforts, prioritized employee well-being, and expanded community healthcare outreach initiatives. From a governance perspective, Lupin has improved transparency, upheld strong ethical standards, strengthened corporate governance systems, and implemented board-level oversight to proactively manage ESG-related risks and opportunities.
About Lupin
Lupin Limited is headquartered in Mumbai, India, and operates in over 100 global markets. The company specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It holds strong market positions in India and the United States across therapeutic areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. With 15 world-class manufacturing facilities and 7 research centers globally, supported by more than 24,000 employees, Lupin remains dedicated to improving patient outcomes through its subsidiaries — Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.